Top Page
CStone Pharmaceuticals
(2616)
CStone Pharmaceuticals (2616) vs. iShares MSCI Hong Kong ETF (EWH)
CStone Pharmaceuticals Business Overview & Revenue Model
CStone Pharmaceuticals Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 177.77M | 407.20M | 463.84M | 481.36M | 243.72M | 1.04B |
| Gross Profit | 21.73M | 240.15M | 304.30M | 278.38M | 136.89M | 797.41M |
| EBITDA | -216.63M | -76.43M | -297.23M | -849.66M | -1.90B | -1.20B |
| Net Income | -242.00M | -91.21M | -367.23M | -902.68M | -1.92B | -1.22B |
Balance Sheet | ||||||
| Total Assets | 1.19B | 1.39B | 1.66B | 1.64B | 2.27B | 3.76B |
| Cash, Cash Equivalents and Short-Term Investments | 690.10M | 672.94M | 1.05B | 1.04B | 1.73B | 3.39B |
| Total Debt | 391.37M | 355.97M | 363.45M | 286.29M | 174.20M | 83.86M |
| Total Liabilities | 876.86M | 1.03B | 1.21B | 1.19B | 1.06B | 808.29M |
| Stockholders Equity | 315.04M | 363.87M | 456.83M | 449.33M | 1.21B | 2.95B |
Cash Flow | ||||||
| Free Cash Flow | -156.05M | -343.18M | -653.89M | -714.29M | -1.63B | -579.52M |
| Operating Cash Flow | -156.05M | -343.18M | -588.84M | -612.47M | -1.48B | -508.07M |
| Investing Cash Flow | -149.95M | -247.68M | 619.61M | 365.12M | -826.55M | 1.18B |
| Financing Cash Flow | 22.58M | -12.90M | 388.36M | 28.47M | 92.30M | 1.39B |
CStone Pharmaceuticals Technical Analysis
CStone Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | HK$11.53B | 45.14 | 13.34% | ― | 206.58% | ― | |
| ― | HK$10.45B | 54.91 | 6.73% | ― | 23.37% | ― | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | HK$11.43B | 17.53 | 35.80% | ― | 59.70% | 239.97% | |
| ― | HK$9.18B | -20.28 | -95.84% | ― | -55.64% | -158.67% | |
| ― | HK$3.34B | ― | -129.05% | ― | ― | -18.99% |
CStone Pharmaceuticals Corporate Events
CStone Pharmaceuticals announced that its CEO, Dr. Jianxin Yang, along with senior management, has increased their shareholding in the company by purchasing 1,000,000 shares, with Dr. Yang acquiring 700,000 shares. This move underscores their confidence in the company’s long-term investment value and growth prospects, as well as their commitment to its future business success. The board views this increase in shareholding as a sign of strong belief in the company’s ability to maintain steady operations and achieve rapid growth, which could positively impact stakeholder confidence.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
CStone Pharmaceuticals announced the first disclosure of preliminary Phase I data for CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, at the 2025 ESMO Annual Congress. The study, conducted in Australia and China, evaluates the safety and antitumor activity of CS2009 in patients with advanced solid tumors, showing favorable safety and tolerability with no dose-limiting toxicity reported. This development marks a significant step in CStone’s efforts to innovate cancer treatment, potentially enhancing its industry positioning and offering new hope for stakeholders involved.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
CStone Pharmaceuticals announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of sugemalimab as a monotherapy for unresectable stage III non-small cell lung cancer (NSCLC) in Europe. This development, based on the pivotal Phase III GEMSTONE-301 study, could solidify sugemalimab’s role as a core immunotherapy for lung cancer, enhancing its market presence and commercial potential. If approved, it will become the second PD-(L)1 antibody available in Europe for stage III NSCLC, addressing a critical unmet need and bringing new hope to patients.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
CStone Pharmaceuticals announced its participation in the 2025 European Society for Medical Oncology Congress, where it will present data from its ongoing clinical trials. The company will showcase the world’s first clinical data for a PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, in advanced solid tumor patients, and provide an update on the ROR1-targeting ADC, CS5001. These presentations highlight CStone’s commitment to advancing innovative cancer therapies and may enhance its positioning in the biopharmaceutical industry.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
CStone Pharmaceuticals announced the enrollment of the first patient in Australia for their global Phase II clinical trial of CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody. This trial, which will expand to the United States, aims to evaluate the drug’s safety, tolerability, and efficacy across multiple tumor types, including lung, liver, colorectal, ovarian, breast, and cervical cancers. The Phase I study showed promising results with favorable safety and significant antitumor activity, suggesting potential advancements in treatment options for various cancers.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
CStone Pharmaceuticals has appointed Mr. Kenneth Howard Jarrett as an independent non-executive director, effective September 23, 2025. Mr. Jarrett brings over 40 years of experience in government and business relations, strategic planning, and key relationship building, having held significant positions in U.S. consulates and private sector organizations. His appointment is expected to strengthen CStone’s strategic and audit committees, potentially enhancing the company’s governance and strategic direction. This move may positively impact CStone’s standing in the biopharmaceutical industry, offering stakeholders confidence in its leadership and future growth prospects.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
CStone Pharmaceuticals has announced the composition of its board of directors and their respective roles within the company. This announcement highlights the company’s leadership structure, which includes a mix of executive, non-executive, and independent directors, and outlines the membership of various board committees, reflecting the company’s commitment to governance and strategic oversight.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
CStone Pharmaceuticals announced that its bispecific antibody CS2015, targeting OX40L and TSLP, will be showcased at the ACAAI 2025 Annual Scientific Meeting in Orlando. This novel therapeutic agent aims to address Type 2 inflammatory diseases such as atopic dermatitis, asthma, and COPD. The presentation highlights CStone’s strategic focus on innovative treatments for autoimmune and inflammation conditions, potentially enhancing its market position and offering new solutions for patients.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
CStone Pharmaceuticals announced the grant of 4,800,000 share options and 1,930,000 restricted share units (RSUs) to select directors and employees under its Post-IPO ESOP and RSU schemes. This strategic move aims to incentivize key personnel and align their interests with the company’s long-term growth objectives, potentially enhancing CStone’s competitive positioning in the biopharmaceutical industry.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
CStone Pharmaceuticals announced a significant decrease in revenue for the first half of 2025, with a drop of 80.5% compared to the same period in 2024, primarily due to price adjustments and a lack of new out-licensing deals. Despite increased research and development expenses, the company reported a shift from profit to loss, highlighting challenges in its financial performance and strategic adjustments in anticipation of future market opportunities.
CStone Pharmaceuticals has announced a board meeting scheduled for August 14, 2025, to review and approve the company’s unaudited interim results for the first half of 2025. The meeting will also consider the possibility of an interim dividend, which could impact shareholder returns and reflect the company’s financial health.
Study Overview: CStone Pharmaceuticals is conducting a Phase III study titled ‘A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of Nofazinlimab (CS1003) in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Advanced Hepatocellular Carcinoma (HCC)’. The study aims to evaluate the efficacy and safety of Nofazinlimab combined with lenvatinib versus a placebo combined with lenvatinib in patients with advanced hepatocellular carcinoma, who have not received prior systemic treatment and are ineligible for locoregional therapy.
CStone Pharmaceuticals announced its participation in the European Society for Medical Oncology (ESMO) Congress 2025, where it will present significant clinical advancements from its Pipeline 2.0. The company will debut the first-in-human Phase Ia data for its novel PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, and the Phase Ib study design for its ROR1-targeting antibody-drug conjugate, CS5001. These developments highlight CStone’s commitment to pioneering cancer treatments and enhancing its position in the global oncology market.